Company Encyclopedia
View More
name
Can-Fite BioPharma
CANF.US
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR.
1.946 T
CANF.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking327/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-264.12%E
    • Profit Margin-1571.25%E
    • Gross Margin100.00%A
  • Growth ScoreD
    • Revenue YoY-16.04%E
    • Net Profit YoY-19.37%D
    • Total Assets YoY30.36%A
    • Net Assets YoY68.78%A
  • Cash ScoreD
    • Cash Flow Margin-6.36%D
    • OCF YoY-16.04%E
  • Operating ScoreE
    • Turnover0.08E
  • Debt ScoreC
    • Gearing Ratio45.80%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Can-Fite BioPharma Showcases Advanced Drug Pipeline at Noble Capital Markets Emerging Growth Conference

    Can-Fite BioPharma Ltd. will present its advanced drug development pipeline, including a Phase III liver cancer trial, at the Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference on December 3rd, 2025, in Boca Raton, Florida. CEO Motti Farbstein will present and meet with investors. A webcast will be available on the company's website. The news was originally published by Can-Fite BioPharma via GlobeNewswire.

    Reuters·
    US
    CANF
    -0.88%
    Reuters·
    US
    CANF
    -0.88%

    Shares of Can-Fite Biopharma are trading higher. The company announced that it aims to advance second veterinary partnership focused on its Phase III anti-cancer drug candidate, Namodenoson, at BioFIT 2025.

    benzinga_article·
    US
    CANF
    -0.88%
    benzinga_article·
    US
    CANF
    -0.88%

    Can-Fite BioPharma Adjusts Warrant Terms to Enhance Market Appeal

    Can-Fite BioPharma Ltd. announced an agreement to reduce the exercise price of warrants for 16,666,666 American Depositary Shares from $0.60 to $0.467 per ADS. This strategic move aims to enhance the attractiveness of the warrants and improve liquidity. Analysts have rated CANF stock as a Sell with a $0.50 price target, citing financial struggles and bearish momentum. Can-Fite BioPharma focuses on developing small molecule drugs for inflammatory, cancer, and liver diseases.

    Tip Ranks·
    US
    CANF
    -0.88%
    Tip Ranks·
    US
    CANF
    -0.88%

    Can-Fite BioPharma’s CF602 Erectile Dysfunction Treatment Receives Patent Allowance in Brazil

    Can-Fite BioPharma Ltd. has received a Notice of Allowance from Brazil's National Institute of Industrial Property for its patent application on CF602, a drug for treating erectile dysfunction, especially in diabetic patients and those unresponsive to current treatments. CF602, an A3 adenosine receptor allosteric modulator, has shown promise in preclinical studies. This patent expands CF602's intellectual property protection beyond major markets.

    Reuters·
    US
    CANF
    -0.88%
    Reuters·
    US
    CANF
    -0.88%

    Pre-market hot trades in US stocks: Can-Fite BioPharma pre-market down 3.31%; TruGolf pre-market down 3.23%

    Can-Fite BioPharma pre-market down 3.31%; TruGolf pre-market down 3.23%; Kazia Therapeutics pre-market up 60.59%; Polestar Automotive UK PLC - CW 27 pre-market up 40.82%; Santech pre-market up 32.21%

    Tracking Unusual Activity·
    US
    CANF
    -0.88%
    US
    TRUG
    -6.35%
    Tracking Unusual Activity·
    US
    CANF
    -0.88%
    US
    TRUG
    -6.35%
    © 2025 Longbridge｜Disclaimer